Webb1 dec. 2024 · SCYNEXIS ( NASDAQ: SCYX ), a biotech focused on treatments for fungal infections, announced Thursday that the FDA approved a second indication for its … Webb30 mars 2024 · Scynexis is due to get $245.5 million in development, regulatory and commercial milestones there — with a separate $15 million tied to an FDA approval. …
SCYNEXIS Reports Fourth Quarter and Full Year 2024 Financial …
Webb31 mars 2024 · SCYNEXIS announced U.S. Food and Drug Administration (FDA) approval of a supplemental NDA for a second indication for BREXAFEMME for the reduction in incidence of recurrent vulvovaginal candidiasis (RVVC). The approval was based on positive results from the pivotal Phase 3 CANDLE study reported in February 2024. Webb7 dec. 2024 · These risks and uncertainties include, but are not limited, to: risks inherent in the regulatory process to obtain FDA approval for ibrexafungerp; SCYNEXIS’s need for … early head start program orlando florida
News - Scynexis
WebbJERSEY CITY, N.J., April 13, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of interim data across a diverse array of infection types from its ongoing Phase 3 FURI and CARES … Webb7 dec. 2024 · JERSEY CITY, N.J., Dec. 07, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to … Webb8 maj 2024 · NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has … early head start program pasco county